However, despite the significant progress made in the landscape of NSCLC, treatment for BRAF mutated NSCLC is not satisfactory due to low incidence of this disease. Dabrafenib and Trametinib is the only approved treatment of choice for BRAF-V600E mutated NSCLC and exhibits poor efficacy against non-V600E mutations. As mentioned above, the common mechanisms of resistance for V600E mutant NSCLC involves MAPK reactivation, loss of length BRAF V600E in concert with expression of a truncated form of mutant protein and enhanced EGFR signaling (49). Here, EGFR is linked to non-small cell lung carcinoma.